This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • 70% of patients have extensive disease at time of diagnosis
  • approximately 75% of patients respond to combination chemotherapy which can induce temporary remission and increase life expectancy
  • in patients with limited disease, thoracic radiotherapy used in conjunction with chemotherapy can improve survival
  • the risk of brain metastases can be reduced with the use of prophylactic radiotherapy in patients who respond to chemotherapy

NICE recommend (1):

  • offer all SCLC patients multidrug platinum-based chemotherapy
  • if the disease responds, offer four to six cycles of chemotherapy. Maintenance treatment is not recommended
  • if limited-stage SCLC then offer thoracic irradiation concurrently with the first or second cycle of chemotherapy or after completion of chemotherapy if there has been at least a good partial response within the thorax
  • if extensive disease then consider thoracic irradiation after chemotherapy if there has been a complete response at distant sites and at least a good partial response within the thorax
  • prophylactic cranial irradiation should be considered for patients with limited disease and complete or good partial response after primary treatment
  • for most cases treatment is palliative
    • radiotherapy may be used to ease pain or bronchial obstruction and pleurodesis may be indicated for recurrent pleural effusions
    • palliative endoscopic laser therapy of obstructive lesions of large airways may also be effective
  • if recurrent small cell lung cancer
    • NICE state that (2):
      • oral topotecan is recommended as an option only for people with relapsed small-cell lung cancer for whom:
        • re-treatment with the first-line regimen is not considered appropriate and
        • the combination of cyclophosphamide, doxorubicin and vincristine (CAV) is contraindicated
      • intravenous topotecan is not recommended for people with relapsed small-cell lung cancer

Reference:

 


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.